ATAZANAVIR
- Product NDC
- 69097-446
- 11-digit product format
- 690970446
- Labeler code
- 69097
- Product ID
- 69097-446_39d9f838-5059-4ac4-be71-96280e2cfe2c
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Atazanavir
- Dosage form
- CAPSULE, GELATIN COATED
- Route
- ORAL
- Labeler
- Cipla USA Inc.
- Application
- ANDA200626
- Marketing category
- ANDA
- Marketing start
- 2018-09-14
- Marketing end
- 0000-00-00
- Substance
- ATAZANAVIR SULFATE
- Active strength
- 300 mg/1
- Pharmacologic classes
- Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], HIV Protease Inhibitors [MoA], Protease Inhibitor [EPC], UDP Glucuronosyltransferases Inhibitors [MoA], UGT1A1 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 69097-446-02 | 69097044602 | 30 CAPSULE, GELATIN COATED in 1 BOTTLE (69097-446-02) | 2018-09-14 | 0000-00-00 | No | No | Current |
| 69097-446-03 | 69097044603 | 60 CAPSULE, GELATIN COATED in 1 BOTTLE (69097-446-03) | 2018-09-14 | 0000-00-00 | No | No | Current |